Why the study?
Does circulating TIMP-1 correlate with echocardiographic markers of diastolic dysfunction in patients with type 2 diabetes and hypertension?
Cross-Sectional (n=120)
Does circulating TIMP-1 correlate with echocardiographic markers of diastolic dysfunction in patients with type 2 diabetes and hypertension?
Effect estimate: Spearman r = -0.544 (hypertensives), r = -0.341 (diabetics)
p-value: p=0.001 (hypertensives), 0.011 (diabetics)
Circulating TIMP-1 levels correlate negatively with early mitral annular velocity (e'), suggesting it may serve as a biomarker for myocardial fibrosis and diastolic dysfunction in patients with hypertension and diabetes.
TIMP-1 may mark fibrosis-related diastolic dysfunction in hypertension and diabetes; leaves open prognostic or therapeutic utility.
BACKGROUND: Tissue inhibitor of metalloproteinase-1 (TIMP-1) is associated with increased fibrosis of the extracellular matrix (ECM). Myocardial stiffness is a feature of diastolic dysfunction. We assessed circulating TIMP-1 as a marker of diastolic dysfunction in patients with type 2 diabetes mellitus (DM) and hypertension, who were compared with healthy controls. METHODS: We recruited 54 patients (43 males; mean age 68 +/- 5 years) with treated type 2 DM (i.e. controlled glycaemia, hypertension, hyperlipidaemia), 35 (30 males; 69 +/- 8 years) treated nondiabetic hypertensives, and 31 healthy controls (18 males; 66 +/- 5 years). Circulating TIMP-1 was measured by ELISA. Using transthoracic echocardiography, the early (E) diastolic mitral inflow velocity was measured with pulse wave Doppler, and the early mitral annular velocity (e'), a recognized index of diastolic relaxation, was measured with tissue Doppler. The E/A ratio was also calculated and isovolumic relaxation time measured. RESULTS: Mean e' levels differed significantly between controls, diabetics and hypertensives (P < 0.0001). Circulating TIMP-1 was significantly different between patients and controls (P = 0.006), but there was no statistically significant difference between the DM and hypertension group. In both groups, only e' was negatively correlated with TIMP-1 levels, with a stronger correlation among the hypertensive patients (Spearman r = -0.544, P = 0.001) when compared with the diabetic group (r = -0.341, P = 0.011). CONCLUSION: Diastolic relaxation is impaired in diabetes and hypertensive patients. The relationship between TIMP-1 and e' may reflect increased myocardial fibrosis and consequent diastolic dysfunction, which may be more prominent in hypertension.
No takes yet. Share an insight, caveat, or question.
Tayebjee et al. (2005) conducted a cross-sectional in Type 2 diabetes mellitus and hypertension (n=120). Circulating TIMP-1 vs. Healthy controls was evaluated on Correlation between circulating TIMP-1 and early mitral annular velocity (e') (Spearman r = -0.544 (hypertensives), r = -0.341 (diabetics), p=0.001 (hypertensives), 0.011 (diabetics)).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: